Briefing

Featured article

FDA withdraws approval of preterm birth drug Makena

Also in this section

News in Numbers

Latest News

Latest Deals

Project Updates

02/23/2024 20:48:35
  • Home | Nanoparticle drug delivery research gets a boost
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Nipro
  • In Depth
  • Covid-19 vaccine success bolsters nanoparticle drug delivery research
  • eConsent in clinical trials: What’s on the horizon?
  • Breathing easy: How digital inhalers are changing asthma treatment
  • Primate models in pharma: What the future holds
  • A decade on, what’s next for CAR-T therapies?
  • FDA’s $7bn plan for 2024: Disclose CMOs, restart Cancer Moonshot
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • Thematic Take
  • Thematic Take: contents
  • Foreword
  • ESG is the most important theme of this decade
  • A timeline of corporate ESG
  • The most pressing ESG concerns for the pharma industry
  • Key trends impacting ESG performance in the healthcare sector
  • Latest news: ESG in pharma
  • Sustainable supply chains: Clinical trials in a new era of limited resources
  • Increase in DPI use could lead to decreases in greenhouse gas emissions
  • Environmental sustainability innovation: Leading companies in anti-malarial compositions
  • Deal activity related to ESG in the pharmaceutical industry since 2020
  • ESG hiring trends in the global pharmaceutical industry since 2020
  • ESG patent applications in the global pharmaceutical industry since 2020
  • Mentions of ESG in pharmaceutical industry company filings since 2020
  • GlobalData Thematic Intelligence
  • Pharma Sponsored Supplements
  • CfPIE
  • Listings
  • Events
  • Rankings
  • Buyer's Guides
  • Next issue
04/27/2023 00:00:00